Parkridge — Chattanooga, Tennessee

Parkridge is a clinical research site located in Chattanooga, Tennessee, United States 37404.

Crixeo Clinical Trials Trust Score: 4/100 (FAILING). This profile has not yet been claimed by the site owner.

Parkridge has participated in 1 clinical trials.

Therapeutic areas: Breast Cancer.

Sponsors: Xoft, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Chattanooga

Browse all research sites in Tennessee · View every site in Chattanooga

• University of Tennessee/Erlanger Oncology and Hematology
• University of Tennessee Erlanger Cardiology
• University Oncology/ Hematology Associates
• Center for Sports Medicine and Orthopaedics; Memorial Hospital
• Children's Hospital at Erlanger
• University of Tennessee-Chattanooga Unit
• University Oncology and Hematology Associates
• Memorial Hospital
• University of Diabetes and Endocrine Consultants
• University Diabetes & Endocrine Consultants /ID# 170392
• University of Tennessee Erlanger Oncology & Hematology
• Parkridge East Hospital

Sponsor Feasibility Report

Trust Score: 4/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Parkridge?

Parkridge has a Crixeo Trust Score of 4/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Parkridge conducted?

Parkridge has 1 clinical trials on record. Their work covers Breast Cancer.

Is Parkridge accredited by Crixeo Clinical Trials?

Parkridge has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Parkridge?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.